Updated Overall Survival Analysis of the DECISION Trial
Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the updated overall survival analysis of the phase III DECISION trial, which looked at sorafenib for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC).
Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the updated overall survival analysis of the phase III DECISION trial, which looked at sorafenib for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC).
Clinical Pearls:
- The primary endpoint of the DECISION trial was reached last year, which showed an improvement from 5.8 months to 10.8 months in the sorafenib arm.
- Overall survival, which was the secondary endpoint in the trial, was a challenging endpoint to reach because 75% of the patients on the study crossed over from the placebo arm to the sorafenib arm.
- The initial analysis did not show a large difference between the placebo arm and the sorafenib arm.
- An additional analysis was presented that accounted for the crossover, but the data is still not statistically significant.
<<<
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
